Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Cash And Cash Equivalents : $2,003 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Cash And Cash Equivalents?

Takeda Pharmaceutical Co's quarterly cash and cash equivalents declined from Jun. 2023 ($2,238.15 Mil) to Sep. 2023 ($2,151.25 Mil) but then stayed the same from Sep. 2023 ($2,151.25 Mil) to Dec. 2023 ($2,002.75 Mil).

Takeda Pharmaceutical Co's annual cash and cash equivalents declined from Mar. 2021 ($8,888.96 Mil) to Mar. 2022 ($7,165.74 Mil) and declined from Mar. 2022 ($7,165.74 Mil) to Mar. 2023 ($3,991.57 Mil).

Takeda Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Takeda Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Cash And Cash Equivalents Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash And Cash Equivalents

Get a 7-Day Free Trial

6,316.95

5,922.08

8,888.96

7,165.74

3,991.57

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															5,078.32	3,991.57	2,238.15	2,151.25	2,002.75

Takeda Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Takeda Pharmaceutical Co (NYSE:TAK) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Takeda Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.